Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
Juanita Crook, Ana Ots, Miren Gaztañaga...
https://pubmed.ncbi.nlm.nih.gov/24958556/Actively Recruiting
Led by British Columbia Cancer Agency · Updated on 2026-06-29
30
Participants Needed
1
Research Sites
261 weeks
Total Duration
Researchers are studying the use of high dose rate HDR partial prostate brachytherapy as a treatment for men with recurrent prostate cancer after initial external beam radiotherapy. The study focuses on men whose cancer has returned locally and who are suitable for this salvage therapy. Advanced imaging with multiparametric MRI mpMRI helps identify the exact site of recurrence, allowing targeted treatment. This study aims to evaluate the safety and effectiveness of HDR brachytherapy in this setting, where local recurrence rates after initial treatment can be high. Participants will receive two fractions of HDR brachytherapy delivered to the identified recurrent tumor site within the prostate. Treatment planning involves mpMRI combined with transrectal ultrasound to define the target area plus a margin for safety. The two treatments are given two weeks apart from a single implant. After treatment, patients will be monitored for side effects, quality of life, and prostate cancer activity using questionnaires and blood tests. During the study, participants will be regularly assessed for treatment-related toxicity and urinary symptoms using standardized questionnaires such as the Expanded Prostate Cancer Index and the International Prostate Symptom Score. Prostate Specific Antigen PSA levels will be monitored to evaluate disease control, and if PSA rises, additional imaging with PSMA PET may be performed. The primary outcome measures include monitoring for late severe gastrointestinal or urinary side effects over 3 to 60 months. Overall participation may last several years to assess long-term safety and effectiveness.
CONDITIONS
Partial Prostate Salvage High Dose Rate Brachytherapy
J
Juanita Crook, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
British Columbia Cancer Agency
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for imaging and evaluation
Duration - Approximately 2 weeks
Participants receive two fractions of high dose rate brachytherapy targeted to the recurrent prostate cancer site, delivered two weeks apart from a single implant.
2 treatment visits plus planning session
Duration - Up to 60 months
Participants are monitored for side effects, quality of life, urinary symptoms, and prostate cancer activity using questionnaires, PSA blood tests, and imaging as needed.
Regular visits for up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Juanita Crook, Ana Ots, Miren Gaztañaga...
https://pubmed.ncbi.nlm.nih.gov/24958556/Elnasif Arrayeh, Antonio C Westphalen, John Kurhanewicz...
https://pubmed.ncbi.nlm.nih.gov/22331003/Robyn Banerjee, Sang-June Park, Erik Anderson...
https://pubmed.ncbi.nlm.nih.gov/25680768/Michael R Da Rosa, Laurent Milot, Linda Sugar...
https://pubmed.ncbi.nlm.nih.gov/25044935/Jim N Rose, Juanita M Crook, Tom Pickles...
https://pubmed.ncbi.nlm.nih.gov/25727178/Josh Mason, Bashar Al-Qaisieh, Peter Bownes...
https://pubmed.ncbi.nlm.nih.gov/25085456/British Columbia Cancer Agency
Lead Sponsor